Guidance and quality standards Awaiting development
Showing 1 to 10 of 339
Title | Type |
---|---|
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095 | Technology appraisal guidance |
Abdominal aortic aneurysm | Quality standard |
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer TS ID 11831 | Technology appraisal guidance |
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833] | Technology appraisal guidance |
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155] | Technology appraisal guidance |
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia TS ID 11768 | Technology appraisal guidance |
Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma TS ID 11823 | Technology appraisal guidance |
Acne | Quality standard |
Adalimumab for treating early Dupuytren's contracture TS ID 11870 | Technology appraisal guidance |
Adrenal dysfunction | Quality standard |